Tatiana A. Tupoleva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tatiana A. Tupoleva has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Dmitriy S. Tikhomirov
National Medical Research Center for Hematology of the Ministry of Health of Russia
31 shared publications - Tatiana Vladimirovna Gaponova
National Medical Research Center for Hematology
10 shared publications - E. N. Ignatova
St. Petersburg State Marine Technical University
6 shared publications - Valerii G. Savchenko
National Medical Research Center for Hematology
6 shared publications - Elena Parovichnikova
National Medical Research Center of Hematology
5 shared publications - Felix P. Filatov
I. Mechnikov Research Institute of Vaccines and Sera
5 shared publications
Latest Publications
- 7 April 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (1)
Successful treatment of orthopneumovirus infection in a patient with primary diffuse B-cell large cell lymphoma of the central nervous system
Introduction . Oncohematological patients are a vulnerable category in relation to orthopneumovirus (OPV), which affects cells of the respiratory epithelium and lung tissue. Aim: to present a clinical observation of the identification of OPV and successful ribavirin treatment of a patient with Diffuse large B-cell lymphoma (DLBCL) and acute respiratory failure (ARF) due to viral pneumonia. Main findings. Patient S., 56 years old, was diagnosed with DLBCL of the central nervous system. After the first course of chemotherapy, he developed acute kidney injury, fever, and bilateral pneumonia with ARF. DNA of Pneumocystis jirovecii was found in bronchoalveolar lavage (BAL) fluid. Therapy with co-trimoxazole and micafungin had no effect. Repeated examination of the BAL fluid did not reveal the DNA of Pneumocystis jirovecii. An extended virological examination revealed OPV RNA in a nasal smear, and ribavirin was added to the therapy. During the following days, normalization of body temperature was noted for the first time, after 3 days there was a regression of ARF. Thus, ribavirin has been shown to be highly effective in cases of confirmed OPV infection.
- 7 April 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (1)
Successful treatment of orthopneumovirus infection in a patient with primary diffuse B-cell large cell lymphoma of the central nervous system
Introduction . Oncohematological patients are a vulnerable category in relation to orthopneumovirus (OPV), which affects cells of the respiratory epithelium and lung tissue. Aim: to present a clinical observation of the identification of OPV and successful ribavirin treatment of a patient with Diffuse large B-cell lymphoma (DLBCL) and acute respiratory failure (ARF) due to viral pneumonia. Main findings. Patient S., 56 years old, was diagnosed with DLBCL of the central nervous system. After the first course of chemotherapy, he developed acute kidney injury, fever, and bilateral pneumonia with ARF. DNA of Pneumocystis jirovecii was found in bronchoalveolar lavage (BAL) fluid. Therapy with co-trimoxazole and micafungin had no effect. Repeated examination of the BAL fluid did not reveal the DNA of Pneumocystis jirovecii. An extended virological examination revealed OPV RNA in a nasal smear, and ribavirin was added to the therapy. During the following days, normalization of body temperature was noted for the first time, after 3 days there was a regression of ARF. Thus, ribavirin has been shown to be highly effective in cases of confirmed OPV infection.
- Open Access
- 5 October 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (3) , 348-358
Blood borne infections in blood donors and the epidemiological situation in the Russian Federation
Introduction. The prevalence of blood-borne infections in the Russia remains high. Between 2016–2023, additional safety measures and requirements were introduced for the examination of donor blood, such as molecular screening for pathogens and additional HBV markers testing. Aim: to analyze the frequency of detection of blood-borne infections in blood donors against the background of the epidemiological situation in the Russian Federation. Materials and methods. Data from National Report (form No. 64) on the production, storage, transportation and clinical use of donor blood and data from the transfusion information system of the National Medical Research Center for Hematology, Russia, were used. Results. The implementation of new safety measures carried the risk of reducing the number of donors, but fortunately, this did not happen. By 2020, the prevalence of socially signifi cant infections among donors in the Russian Federation decreased from 18,064 cases to 5,596 cases. However, there was an increase in 2021. This trend correlates with the dynamics of morbidity rates among the population of the Russian Federation. The approach to the registration and control of blood-borne infections for donors differs from that of the general population. For example, HIV-vulnerable population groups are recommended only for voluntary testing, thus, the true incidence rate of HIV in Russia may exceed the offi cial data. A similar problem is observed with viral hepatitis. HBV markers were found in donors of blood and its components more often than other infectious markers. However, among the population of the Russian Federation, the incidence rate of HBV is lower than that of HIV infection (9 versus 40 cases per 100,000 population, respectively). Conclusion. The prevalence of blood-borne infections among the population of the Russian Federation creates a threat of infected people entering the donor population. Surveillance and control of viral hepatitis B and C requires improvement.
- 5 October 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (3) , 348-358
Open AccessBlood borne infections in blood donors and the epidemiological situation in the Russian Federation
Introduction. The prevalence of blood-borne infections in the Russia remains high. Between 2016–2023, additional safety measures and requirements were introduced for the examination of donor blood, such as molecular screening for pathogens and additional HBV markers testing. Aim: to analyze the frequency of detection of blood-borne infections in blood donors against the background of the epidemiological situation in the Russian Federation. Materials and methods. Data from National Report (form No. 64) on the production, storage, transportation and clinical use of donor blood and data from the transfusion information system of the National Medical Research Center for Hematology, Russia, were used. Results. The implementation of new safety measures carried the risk of reducing the number of donors, but fortunately, this did not happen. By 2020, the prevalence of socially signifi cant infections among donors in the Russian Federation decreased from 18,064 cases to 5,596 cases. However, there was an increase in 2021. This trend correlates with the dynamics of morbidity rates among the population of the Russian Federation. The approach to the registration and control of blood-borne infections for donors differs from that of the general population. For example, HIV-vulnerable population groups are recommended only for voluntary testing, thus, the true incidence rate of HIV in Russia may exceed the offi cial data. A similar problem is observed with viral hepatitis. HBV markers were found in donors of blood and its components more often than other infectious markers. However, among the population of the Russian Federation, the incidence rate of HBV is lower than that of HIV infection (9 versus 40 cases per 100,000 population, respectively). Conclusion. The prevalence of blood-borne infections among the population of the Russian Federation creates a threat of infected people entering the donor population. Surveillance and control of viral hepatitis B and C requires improvement.
- Open Access
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 40-50
Inherited chromosomally integrated Human herpesvirus 6 in patients with blood system diseases
Introduction. Human herpesvirus 6 (HHV-6) is an opportunistic agent causing various complications in patients with hematological diseases. The virus has a unique ability to integrate into telomeres of human chromosomes, which makes hereditary transmission of the viral genome possible. This form of the virus is called inherited chromosomally integrated HHV-6 (iciHHV-6). The iciHHV-6 frequency among patients with blood system diseases is unknown and its signifi cance for clinical practice remains insufficiently studied.Aim — to determine the prevalence of ichHHV-6 in patients with hematological diseases.Materials and methods. Clinical and laboratory data in 4,998 adult patients treated at the National Medical Research Center for Hematology (Moscow, Russia) from 2020 to 2024 were analyzed. Clinical materials obtained from patients were examined by molecular-biological methods for the presence of HHV-6 DNA.Results. IciHHV-6 was confirmed in 14 out of 4,998 (0.26 %) enrolled patients. 5 patients (38,5 %) had clinical manifestations of herpesvirus infection during treatment, while the other 9 patients (61.5 %) showed no signs of the infection. 5 of 14 iciHHV-6-positive patients underwent hematopoietic stem cell transplantation. Criteria and laboratory tests for suspicion for iciHHV-6 were designed and successfully verified, which made it possible to suspect and prove the presence of hci-HCV-6.Conclusion. The presence of ichHHV-6 among patients with hematological diseases was detected in 0.26 % of cases. The high concentration of HCV-6 DNA during polymerase chain reaction testing, as well as the absence of negative virological results during antiviral therapy, make it possible to suspect HCV-HCV-6. Screening for iciHHV-6 by qPCR of hair follicles and nails is recommended for patient with high viremia. A positive result in such tests confirms iciHHV-6-positive status. The efficiency of antiviral therapy in iciHHV-6-individuals requires further research. During transplantation of allogeneic hematopoietic stem cells to a recipient-carrier of hci-HCV-6, HCV-6 reactivation, asymptomatic persistence of high viremia, and a dramatic decrease of the viral load are all possible.
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 40-50
Open AccessInherited chromosomally integrated Human herpesvirus 6 in patients with blood system diseases
Introduction. Human herpesvirus 6 (HHV-6) is an opportunistic agent causing various complications in patients with hematological diseases. The virus has a unique ability to integrate into telomeres of human chromosomes, which makes hereditary transmission of the viral genome possible. This form of the virus is called inherited chromosomally integrated HHV-6 (iciHHV-6). The iciHHV-6 frequency among patients with blood system diseases is unknown and its signifi cance for clinical practice remains insufficiently studied.Aim — to determine the prevalence of ichHHV-6 in patients with hematological diseases.Materials and methods. Clinical and laboratory data in 4,998 adult patients treated at the National Medical Research Center for Hematology (Moscow, Russia) from 2020 to 2024 were analyzed. Clinical materials obtained from patients were examined by molecular-biological methods for the presence of HHV-6 DNA.Results. IciHHV-6 was confirmed in 14 out of 4,998 (0.26 %) enrolled patients. 5 patients (38,5 %) had clinical manifestations of herpesvirus infection during treatment, while the other 9 patients (61.5 %) showed no signs of the infection. 5 of 14 iciHHV-6-positive patients underwent hematopoietic stem cell transplantation. Criteria and laboratory tests for suspicion for iciHHV-6 were designed and successfully verified, which made it possible to suspect and prove the presence of hci-HCV-6.Conclusion. The presence of ichHHV-6 among patients with hematological diseases was detected in 0.26 % of cases. The high concentration of HCV-6 DNA during polymerase chain reaction testing, as well as the absence of negative virological results during antiviral therapy, make it possible to suspect HCV-HCV-6. Screening for iciHHV-6 by qPCR of hair follicles and nails is recommended for patient with high viremia. A positive result in such tests confirms iciHHV-6-positive status. The efficiency of antiviral therapy in iciHHV-6-individuals requires further research. During transplantation of allogeneic hematopoietic stem cells to a recipient-carrier of hci-HCV-6, HCV-6 reactivation, asymptomatic persistence of high viremia, and a dramatic decrease of the viral load are all possible.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 14 (1)
Clinical and immunological criteria for predicting the chronic course of herpesvirus infections in the outcome of infectious mononucleosis of various etiologies in children
Клинические и иммунологические критерии хронизации течения герпесвирусных инфекций в исходе мононуклеозоподобного синдрома различной этиологии у детей
- 1 January 2025
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 14 (1)
Open AccessClinical and immunological criteria for predicting the chronic course of herpesvirus infections in the outcome of infectious mononucleosis of various etiologies in children
Клинические и иммунологические критерии хронизации течения герпесвирусных инфекций в исходе мононуклеозоподобного синдрома различной этиологии у детей
- Open Access
- 9 November 2024
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 69 (5) , 449-458
Mutations in human cytymegalovirus (Orthoherpesviridae: Herpesvirales: Cytomegalovirus: Cytomegalovirus humanbeta 5) UL97 gene lead to increase in viremia duration and poor antiviral response in recipients of allogeneic hematopoietic stem cells
Introduction. Human cytomegalovirus (Orthoherpesviridae: Herpesvirales: Cytomegalovirus: Cytomegalovirus humanbeta 5) (HCMV) is one of the most commonly detected viruses in recipients of allogeneic hematopoietic stem cell (allo-HSCT) transplants. However, the emergence of resistance to antiviral drugs such as ganciclovir (GCV) poses a challenge in managing these patients. This study aims to investigate the prevalence and impact of mutations in the HCMV UL97 gene associated with resistance to GCV on the course of infection among allo-HSCT patients. Materials and methods. The study examined the association between UL97 mutations and the clinical course of HCMV infection in allo-HSCT patients. Genetic sequencing was performed to identify mutations, and their impact on viral replication and resistance to GCV was assessed. Results and discussion. Six mutations were identified (D490A, T502A, C592G, C592F, E596G, C603W). C592G, C592F, E596G, and C603W are associated with resistance to antiviral drugs, while D490A and T502A described for the first time. When comparing patients with wild-type and those carrying the mutant variant, several parameters of peripheral blood were significantly lower in the former group. The median time to peak viral load following allo-HSCT, duration of viremia, and rate of virological response to high-dose therapy also differed significantly between the two groups. Conclusion. It was shown that approximately one third (4 out of 14) of allogeneic stem cell transplant recipients had mutations associated with resistance to GCV. Patients carrying the mutant variant of HCMV had longer viremia and took longer to achieve a negative virological test result after starting high-dose therapy. Performing genotyping may help make more evidence-based therapeutic decisions.
- 9 November 2024
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 69 (5) , 449-458
Open AccessMutations in human cytymegalovirus (Orthoherpesviridae: Herpesvirales: Cytomegalovirus: Cytomegalovirus humanbeta 5) UL97 gene lead to increase in viremia duration and poor antiviral response in recipients of allogeneic hematopoietic stem cells
Introduction. Human cytomegalovirus (Orthoherpesviridae: Herpesvirales: Cytomegalovirus: Cytomegalovirus humanbeta 5) (HCMV) is one of the most commonly detected viruses in recipients of allogeneic hematopoietic stem cell (allo-HSCT) transplants. However, the emergence of resistance to antiviral drugs such as ganciclovir (GCV) poses a challenge in managing these patients. This study aims to investigate the prevalence and impact of mutations in the HCMV UL97 gene associated with resistance to GCV on the course of infection among allo-HSCT patients. Materials and methods. The study examined the association between UL97 mutations and the clinical course of HCMV infection in allo-HSCT patients. Genetic sequencing was performed to identify mutations, and their impact on viral replication and resistance to GCV was assessed. Results and discussion. Six mutations were identified (D490A, T502A, C592G, C592F, E596G, C603W). C592G, C592F, E596G, and C603W are associated with resistance to antiviral drugs, while D490A and T502A described for the first time. When comparing patients with wild-type and those carrying the mutant variant, several parameters of peripheral blood were significantly lower in the former group. The median time to peak viral load following allo-HSCT, duration of viremia, and rate of virological response to high-dose therapy also differed significantly between the two groups. Conclusion. It was shown that approximately one third (4 out of 14) of allogeneic stem cell transplant recipients had mutations associated with resistance to GCV. Patients carrying the mutant variant of HCMV had longer viremia and took longer to achieve a negative virological test result after starting high-dose therapy. Performing genotyping may help make more evidence-based therapeutic decisions.
- Open Access
- 3 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 215-223
Clinical significance of infections caused by human 6A and 6B herpes viruses in allogeneic hematopoietic stem cells recipients in the post-transplant period
Allogeneic hematopoietic stem cells transplantation is an effective method for the treatment of hematologic malignancies and other blood system diseases. Infections caused by human 6A and 6B herpes viruses are one of the leading causes of complications and mortality in hematology patients after allogeneic hematopoietic stem cell transplantation, especially in the first 100 days after transplantation. This review discusses the clinical features of infections caused by human herpes viruses 6A and 6B, their impact on the development of post-transplant complications, including graft-versus-host disease and graft failure, as well as methods of prevention and treatment.
- 3 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 215-223
Open AccessClinical significance of infections caused by human 6A and 6B herpes viruses in allogeneic hematopoietic stem cells recipients in the post-transplant period
Allogeneic hematopoietic stem cells transplantation is an effective method for the treatment of hematologic malignancies and other blood system diseases. Infections caused by human 6A and 6B herpes viruses are one of the leading causes of complications and mortality in hematology patients after allogeneic hematopoietic stem cell transplantation, especially in the first 100 days after transplantation. This review discusses the clinical features of infections caused by human herpes viruses 6A and 6B, their impact on the development of post-transplant complications, including graft-versus-host disease and graft failure, as well as methods of prevention and treatment.
- Open Access
- 14 March 2024
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 69 (1) , 22-30
Human herpes virus type 6 (Orthoherpesviridae: Roseolovirus): features of epidemiology and diagnosis
Human herpes virus 6A and human herpes virus 6B (HHV-6A and HHV-6B) are ubiquitous viruses. The spectrum of clinical manifestations of HHV-6A/B infections is quite wide. The current understanding of the natural history and laboratory diagnosis of HHV-6A and HHV-6B, including their chromosome-integrated form, serves the basis for development of the tools for HHV-6 epidemiological monitoring. This article addresses the epidemiology and diagnosis of infections caused by these viruses, including ones in patients after transplantation of solid organs and allogeneic hematopoietic stem cells.
- 14 March 2024
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 69 (1) , 22-30
Open AccessHuman herpes virus type 6 (Orthoherpesviridae: Roseolovirus): features of epidemiology and diagnosis
Human herpes virus 6A and human herpes virus 6B (HHV-6A and HHV-6B) are ubiquitous viruses. The spectrum of clinical manifestations of HHV-6A/B infections is quite wide. The current understanding of the natural history and laboratory diagnosis of HHV-6A and HHV-6B, including their chromosome-integrated form, serves the basis for development of the tools for HHV-6 epidemiological monitoring. This article addresses the epidemiology and diagnosis of infections caused by these viruses, including ones in patients after transplantation of solid organs and allogeneic hematopoietic stem cells.
- Open Access
- 16 November 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (3) , 382-389-389
Safety of plasma-derived blood products transfusions harvested from anti-SARS-CoV-2 positive and negative donors
Introduction. Testing for antibodies to the causative agent COVID-19 is not mandatory for donor blood or its components. It is unknown whether transfusion of plasma-containing blood components from seropositive donors is a safe procedure especially for immunocompromised hematological patients. Aim. To assess the frequency of adverse reactions and complications in hematological patients after transfusions of plasma-derived blood products harvested from anti-SARS-CoV-2 positive and negative donors. Material and Methods. 9152 transfusions of components harvested from anti-SARS-CoV-2 positive and negative donors were carried out from April 29, 2020 to January 21, 2022 at the NMRC for Hematology. Post-transfusion reactions and complications were analyzed in 576 hematological patients. 2059 plasma units, 327 cryosupernatant plasma units and 6766 cryoprecipitate doses were assessed. The occurrence of adverse reactions (hyperthermia) and complications within two hours after transfusion were evaluated. Results. Among 9152 blood units, anti-SARS-CoV-2 were detected in 2660 (29 %) cases and 6492 (71 %) were antibodies free. The analysis of adverse reactions and complications showed no significant differences in the incidence of adverse reactions in recipients after anti-SARS-CoV-2 positive and negative blood unit transfusions. Conclusion. There were no significant differences in the number of post-transfusion reactions when using donor blood components (fresh frozen plasma, cryosupernatant plasma, cryoprecipitate) obtained from donors in whose blood antibodies to SARS-CoV-2 were detected or not detected. Plasma-derived blood products from seropositive donors with a high degree of probability can be used to correct the plasma hemostasis path in hematological patients along with components prepared from seronegative donors.
- 16 November 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (3) , 382-389-389
Open AccessSafety of plasma-derived blood products transfusions harvested from anti-SARS-CoV-2 positive and negative donors
Introduction. Testing for antibodies to the causative agent COVID-19 is not mandatory for donor blood or its components. It is unknown whether transfusion of plasma-containing blood components from seropositive donors is a safe procedure especially for immunocompromised hematological patients. Aim. To assess the frequency of adverse reactions and complications in hematological patients after transfusions of plasma-derived blood products harvested from anti-SARS-CoV-2 positive and negative donors. Material and Methods. 9152 transfusions of components harvested from anti-SARS-CoV-2 positive and negative donors were carried out from April 29, 2020 to January 21, 2022 at the NMRC for Hematology. Post-transfusion reactions and complications were analyzed in 576 hematological patients. 2059 plasma units, 327 cryosupernatant plasma units and 6766 cryoprecipitate doses were assessed. The occurrence of adverse reactions (hyperthermia) and complications within two hours after transfusion were evaluated. Results. Among 9152 blood units, anti-SARS-CoV-2 were detected in 2660 (29 %) cases and 6492 (71 %) were antibodies free. The analysis of adverse reactions and complications showed no significant differences in the incidence of adverse reactions in recipients after anti-SARS-CoV-2 positive and negative blood unit transfusions. Conclusion. There were no significant differences in the number of post-transfusion reactions when using donor blood components (fresh frozen plasma, cryosupernatant plasma, cryoprecipitate) obtained from donors in whose blood antibodies to SARS-CoV-2 were detected or not detected. Plasma-derived blood products from seropositive donors with a high degree of probability can be used to correct the plasma hemostasis path in hematological patients along with components prepared from seronegative donors.
- Open Access
- 18 July 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (2) , 202-218
Comparative study of the quality of screening of donated blood for the presence of molecular markers of viral infections
Introduction. Transfusions of donor blood components are indispensable in providing medical care for a large number of conditions and diseases. Therefore, the issue of improving the quality and safety of transfusions is relevant for healthcare worldwide.Aim — to assess the quality of donor blood screening for HIV, HBV and HCV by PCR in several Russian blood banks.Methods: PCR, CLIA and ELISA.Results. A study was conducted to assess the quality of molecular screening of donated blood in medical organizations, which was carried out in two stages. Two different kits of control samples for each project stage were created and delivered to the project participants (blood banks). Each kit contained samples with or without HBV DNA / HIV RNA / HCV RNA. The first stage’s kit contained 40 samples, the second one — 10 samples. Thus, project participants performed 13 series of test runs (520 tests) on the first stage and 8 series of runs (80 tests) on the second one. The number kits copies sent to one participant was determined by the participant’s laboratory equipment. Participants who used the Cobas performed 330 tests, of which 255 were incorrect. Participants using the Procleix performed 40 tests, and 29 tests gave a false result. 140 samples were tested by AmpliSens, and results in 86 cases were incorrect. One participant used Vector-Best test kits and performed 40 tests, 16 of which returned incorrect. In total, 355 samples containing HBV DNA, 121 samples containing HCV RNA, and 82 samples containing HIV RNA were provided to project participants. HBV DNA was detected in 191 (53.8 %) of 355 samples, HCV RNA was detected in 119 (98.3 %) of 121 samples, and HIV RNA was detected in 76 (92.7 %) of 82 samples.Conclusion. The proportion of inconsistencies in the results increased depending on the decrease in the concentration of the marker being determined. Participants demonstrated the best performance results if they were using branded equipment. Such participants received the least inconsistencies. The biggest issue concerned HBV DNA detection due to a lower viremia of this pathogen. All samples with low HBV DNA levels contained anti-HBc, which indicates potential latent HBV. Therefore, it is appropriate to include anti-HBc in the routine screening of donated blood.
- 18 July 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (2) , 202-218
Open AccessComparative study of the quality of screening of donated blood for the presence of molecular markers of viral infections
Introduction. Transfusions of donor blood components are indispensable in providing medical care for a large number of conditions and diseases. Therefore, the issue of improving the quality and safety of transfusions is relevant for healthcare worldwide.Aim — to assess the quality of donor blood screening for HIV, HBV and HCV by PCR in several Russian blood banks.Methods: PCR, CLIA and ELISA.Results. A study was conducted to assess the quality of molecular screening of donated blood in medical organizations, which was carried out in two stages. Two different kits of control samples for each project stage were created and delivered to the project participants (blood banks). Each kit contained samples with or without HBV DNA / HIV RNA / HCV RNA. The first stage’s kit contained 40 samples, the second one — 10 samples. Thus, project participants performed 13 series of test runs (520 tests) on the first stage and 8 series of runs (80 tests) on the second one. The number kits copies sent to one participant was determined by the participant’s laboratory equipment. Participants who used the Cobas performed 330 tests, of which 255 were incorrect. Participants using the Procleix performed 40 tests, and 29 tests gave a false result. 140 samples were tested by AmpliSens, and results in 86 cases were incorrect. One participant used Vector-Best test kits and performed 40 tests, 16 of which returned incorrect. In total, 355 samples containing HBV DNA, 121 samples containing HCV RNA, and 82 samples containing HIV RNA were provided to project participants. HBV DNA was detected in 191 (53.8 %) of 355 samples, HCV RNA was detected in 119 (98.3 %) of 121 samples, and HIV RNA was detected in 76 (92.7 %) of 82 samples.Conclusion. The proportion of inconsistencies in the results increased depending on the decrease in the concentration of the marker being determined. Participants demonstrated the best performance results if they were using branded equipment. Such participants received the least inconsistencies. The biggest issue concerned HBV DNA detection due to a lower viremia of this pathogen. All samples with low HBV DNA levels contained anti-HBc, which indicates potential latent HBV. Therefore, it is appropriate to include anti-HBc in the routine screening of donated blood.
- Open Access
- 27 June 2023
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 22 (2) , 28-33
Prevalence and features of the course of HIV/HCV co-infection in pregnant women
Распространенность и особенности течения ВИЧ/ВГС ко-инфекции у беременных
- 27 June 2023
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 22 (2) , 28-33
Open AccessPrevalence and features of the course of HIV/HCV co-infection in pregnant women
Распространенность и особенности течения ВИЧ/ВГС ко-инфекции у беременных